Aap Implantate Ag · XETR:AAQ1
Aap Implantate — German Equity Forum 2018
24 slides from Aap Implantate's conference presentation, Nov 27, 2018
Slide 1: aap Implantate AG Corporate Presentation
aap Implantate AG Corporate Presentation German Equity Forum 2018 Making Trauma Treatment Bruke Seyoum Alemu, CEO Better and Cost-Effective Marek Hahn, CFO Frankfurt am Main, November 27, 2018
Slide 2: Safe Harbor Statement
Safe Harbor Statement Our publication may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual
Slide 3: aap at a Glance
aap at a Glance Pure player in trauma Orthopedic company focused on trauma addressing unmet needs in trauma surgery: ➢ Simplify operation techniques for im- and explantation of implants ➢ Reduce surgical site infections (SSI) caused by implants ➢ Avoid second operations by using resorbable metal imp
Slide 4: Sustainability & Value creation
Our Balanced Portfolio of Innovations Addressing unmet needs and challenges High Incremental innovations Breakthrough innovations Sustainability & Value creation Sell more to existing Reach new customers Shift existing markets Create new market Low customers Impact on market Our source of value crea
Slide 5: Platform Technology – LOQTEQ®
Platform Technology – LOQTEQ® Unmet need / challenge: Simplify operation techniques for im- and explantation IP-protected Our response: Locking compression technology by aap ➢ Angular stable compression in one step ➢ Strong clinical evidence of no cold-welding ➢ Comprehensive plates and screws portf
Slide 6: Platform Technology – LOQTEQ®
Platform Technology – LOQTEQ® ➢ Comprehensive ➢ Patented ➢ High Quality ➢ Clinical & Economical Advantage Indication Coverage > 90% 6
Slide 7: Surgical Site Infections (SSI)
Surgical Site Infections (SSI) Outlining the market potential for aap’s silver coating technology ➢ SSI are burdening global economies enormously ➢ “SSI is the most frequent type of health care associated infections (HAI) in low- and middle-income countries affecting up to 1/3 of patients who have u
Slide 8: Platform Technology – Silver Coating
Platform Technology – Silver Coating Unmet need / challenge: Reduce surgical site infections (SSI) caused by implants IP-protected Our response: Antibacterial silver coating by aap ➢ Stable coating with high antibacterial efficacy and biocompatibility ➢ Cost-effective coating technology ➢ Platform t
Slide 9: Silver Coating Technology – Update (1/2)
Silver Coating Technology – Update (1/2)* Significant progress with respect to targeted market approval process ➢ Convincing results of animal study with AO Research Institute Davos (“non-inferiority”) as milestone on the way to a human clinical study ➢ EUR 0.7m funding from Federal Ministry of Educ
Slide 10: Silver Coating Technology – Update (2/2)
Silver Coating Technology – Update (2/2)* Scope of LOQTEQ® antibacterial pre market human study ➢ Prospective, controlled, subject and observer-blind, multi-center study with LOQTEQ® antibacterial locking plates in subjects with fractures of distal tibia ➢ 230 patients in Germany, Austria and USA ➢
Slide 11: Platform Technology – Magnesium Implants
Platform Technology – Magnesium Implants Unmet need / challenge: Avoid second operations by using resorbable metal implants IP-protected Our response: Coated Resorbable Magnesium Implant Technology by aap ➢ Good biomechanical properties combined with a moderate and controllable resorption rate ➢ Cos
Slide 12: LOQTEQ® – Roadmap
LOQTEQ® – Roadmap Addressing unmet needs in trauma through innovations 12
Slide 13: aap's Equity Story – Pure Player in Trauma
aap’s Equity Story – Pure Player in Trauma Why invest in aap? Making Trauma Treatment Better and Cost-Effective ➢ Innovative IP-protected products and platform technologies addressing unmet needs and challenges in trauma ➢ LOQTEQ®: Addressing the fastest growing trauma segments ➢ Silver Coating: Add
Slide 14: Many thanks for your attention!
Many thanks for your attention! Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de IR-app:
Slide 15: Appendix
Appendix qos
Slide 16: Key results and progress 9M/2018 (1/2)
Key results and progress 9M/2018 (1/2) ➢ Sales and Earnings ▪ Trauma sales growth of 6% yoy to EUR 8.2 million (9M/2017: EUR 7.8 million) ▪ Continued positive development in focus market Germany (+12% yoy) and international business (ex-US, +28% yoy) Total sales growth ex-US of 23% ▪ EBITDA improv
Slide 17: Key results and progress 9M/2018 (2/2)
Key results and progress 9M/2018 (2/2) ➢ LOQTEQ® ▪ Biomechanical study confirms already clinically observed good explantation properties of LOQTEQ® compared with market leader technology ▪ Working on European approval of various polyaxial LOQTEQ® systems ▪ Development of sterile packaging for implan
Slide 18: Financial Figures 9M/2018 (1/2)
Financial Figures 9M/2018 (1/2) (in KEUR) Sales (reported) 9M/2018 9M/2017 Change Trauma 8,238 7,785 +6% Germany 2,080 1,849 +12% North America 1,687 2,450 -31% North America Distributors 1,626 1,877 -13% North America Global Partners 61 573 -89% International 4,471 3,486 +28% Other (mainly disconti
Slide 19: Financial Figures 9M/2018 (2/2)
Financial Figures 9M/2018 (2/2) (in EUR million) Capital Structure 30/09/2018 31/12/2017 Change Total Assets 44.6 50.5 -12% Equity Ratio 83% 84% Cash Flow and Investments 30/09/2018 30/09/2017 Change Operative cash flow -3.7 -4.4 +15% Total investing activities 2.1 1.4 +46% Cash Structure 30/09/2018
Slide 20: Shareholder Structure
Shareholder Structure* (Shareholdings in aap ≥ 3%, according to our information) ➢ High degree of stability with a base of long-term oriented investors ➢ Market Cap of approx. EUR 33 million* 15.81% Ratio Capital Management B.V., Netherlands Noes Beheer B.V., Netherlands Jürgen W. Krebs, Switzerland
Slide 21: Many thanks for your attention!
Many thanks for your attention! Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de IR-app:
Slide 22: Notes
Notes cap
Slide 23: Notes
Notes cap
Slide 24: Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations
Lorenzweg 5 • 12099 Berlin • Germany Fabian Franke Manager Investor Relations Tel.: +49 30 750 19 – 134 Fax: +49 30 750 19 – 290 E-Mail: ir@aap.de IR-app: